Emcure Pharmaceuticals Ltd.

NSE: EMCURE · Healthcare

₹2,212.80-1.43%06 Nov 2026

Ask the data

Instant answers about Emcure Pharmaceuticals Ltd. — computed from its filings, no language model

Market cap₹41,979 cr

Current price₹2,212.80

High / Low₹2,245 / ₹1,319

P/E38.4

P/B7.86

Book value₹281.7

ROE20.5%

ROCE24.2%

Debt / equity0.27

Dividend yield0.14%

EPS (TTM)₹57.64

Face value₹10

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

	FY25	FY26
Revenue	7,896	9,204
EBITDA	1,474	1,865
Operating margin	18.7%	20.3%
Interest	176	144
Depreciation	384	415
Profit before tax	971	1,287
Tax	264	346
Net profit	681	924
EPS ₹	36.43	48.77
Operating cash flow	852	944
Capex	407	548
Dividend paid	0	57
Total assets	8,233	9,612
Equity	4,446	4,950

Quarterly performance

last 10 quarters · ₹ crore

showing latest 8 of 10 periods

	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	1,815	2,002	1,963	2,116	2,101	2,270	2,363	2,470	2,580	2,820
Operating profit	336	381	355	402	417	475	493	480	532	588
Operating margin	18.5%	19.0%	18.1%	19.0%	19.8%	20.9%	20.8%	19.4%	20.6%	20.8%
Other income	23	36	4	4	4	3	2	4	2	3
Interest	59	46	32	39	27	33	38	46	32	36
Depreciation	94	97	97	97	99	105	105	106	110	110
Profit before tax	207	273	230	261	291	341	314	341	394	446
Tax	55	72	74	63	76	90	82	97	101	121
Net profit	144	195	154	189	207	243	231	243	294	326
EPS ₹	7.95	10.33	8.12	9.97	10.92	12.85	12.16	12.84	15.50	17.16
Revenue YoY	—	—	—	—	15.7%	13.4%	20.4%	16.7%	22.8%	24.3%
Profit YoY	—	—	—	—	43.6%	25.1%	50.0%	28.8%	42.1%	33.7%

Returns & margins

trailing-twelve-month, per quarter

	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	15.3%	16.7%	16.7%	18.3%	18.7%	20.4%	20.5%
ROCE	22.2%	23.1%	20.6%	22.1%	23.2%	25.0%	24.2%
Net margin	8.6%	9.1%	9.4%	9.8%	10.0%	10.4%	10.7%
EBITDA margin	18.7%	19.0%	19.5%	20.2%	20.3%	20.5%	20.4%
Debt / equity	0.16	0.16	0.28	0.28	0.24	0.24	0.27
Interest coverage	6.53	8.34	9.63	9.85	9.96	10.36	10.86
Asset turnover	0.96	0.99	0.90	0.94	0.96	1.01	1.01

Balance sheet

equity vs borrowings over time · ₹ crore

	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	189	189	190	190	190
Other equity / reserves	3,929	4,257	4,553	4,760	5,154
Total equity	4,118	4,446	4,743	4,950	5,344
Borrowings	942	732	1,344	1,204	1,467
Current liabilities	2,832	2,668	3,686	3,912	3,839
Non-current liabilities	989	923	822	724	981
Total assets	8,124	8,233	9,393	9,612	10,164
Property, plant & equipment	1,892	1,954	1,930	1,960	1,986
Capital work-in-progress	178	124	144	172	328
Investments	64	95	42	20	20
Inventories	1,752	1,932	2,305	2,398	2,505
Receivables	2,029	2,002	2,300	2,563	2,731
Cash & equivalents	162	156	472	137	137

Cash flow

annual · ₹ crore · line = free cash flow

	FY25	FY26
Cash from operations	852	944
Cash from investing	-94	-1,193
Cash from financing	-814	343
Capex	407	548
Free cash flow	445	396
Dividends paid	0	57

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹1,986 cr20%

CWIP

₹328 cr3%

Investments

₹20 cr0%

Inventories

₹2,505 cr25%

Receivables

₹2,731 cr27%

Cash & equivalents

₹137 cr1%

Other assets

₹2,457 cr24%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%
Emcure Pharmaceuticals Ltd.	41,979	2,212.80	38.4	7.86	20.5%

StoxGud checklist: Bullish setup · 9/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month+15.4%

6 months+32.9%

1 year+65.2%

3Y CAGR—

5Y CAGR—

10Y CAGR—

50-day avg₹1,913.68

200-day avg₹1,737.82

RSI (14)81

Compare Emcure Pharmaceuticals Ltd. with

Glaxosmithkline Pharmaceuticals vs Emcure Pharmaceuticals Emcure Pharmaceuticals vs Ajanta Pharmaceuticals Emcure Pharmaceuticals vs Narayana Hrudayalaya Emcure Pharmaceuticals vs Sai Life Sciences

FAQs

What is the share price of Emcure Pharmaceuticals Ltd.?

Emcure Pharmaceuticals Ltd. (EMCURE) closed at ₹2,212.80 on NSE on 06 Nov 2026.

What is the market cap of Emcure Pharmaceuticals Ltd.?

₹41,979 crore at the latest close.

What is the P/E ratio of Emcure Pharmaceuticals Ltd.?

38.4, on trailing-twelve-month earnings from its filings.

How fast is Emcure Pharmaceuticals Ltd. growing?

Emcure Pharmaceuticals Ltd.: Latest-quarter revenue is up 24.3% year on year, profit up 33.7%.

How profitable is Emcure Pharmaceuticals Ltd.?

On a trailing-twelve-month basis return on equity is 20.5%, return on capital employed 24.2%, operating margin 20.4%, net margin 10.7%.

How much debt does Emcure Pharmaceuticals Ltd. have?

Emcure Pharmaceuticals Ltd. is lightly geared: debt to equity is 0.27 with borrowings of ₹1,467 cr against cash of ₹137 cr (balance sheet of 2026-09-30). Operating profit covers interest 10.9 times.

Financials parsed from Emcure Pharmaceuticals Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from JUN '24, annual from FY25, balance sheet from Sep '24. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.